The label update provides an option for patients who have received at least 1 approved systemic therapy if TNF blockers are clinically inadvisable.
Topline data were announced from a phase 3 trial evaluating secukinumab in patients with polymyalgia rheumatica.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback